CJC-1295 with DAC
CJC-1295 with DAC is a long-acting synthetic GHRH analogue carrying a Drug Affinity Complex that binds serum albumin, extending its duration of action to several days.
Regulatory status: Not approved by the FDA for any human use. The human record consists of a single published pharmacology study rather than a full clinical development programme.
Default vial
5 mg
Default mix
2 mL
Reported range
1–2 mg
Draw (U-100)
80 u
Long-acting; dosed once or twice weekly rather than daily.
What it is
- A modified GHRH(1-29) analogue conjugated to a maleimidopropionic acid group — the Drug Affinity Complex — which binds albumin in the body.
- A GHRH-receptor agonist, like sermorelin and tesamorelin.
- Reported to have a markedly extended half-life compared with native GHRH fragments because of albumin binding.
- Given by subcutaneous injection in the identified human study, which evaluated single and repeated dosing.
How it is described to act
- 1
Administered subcutaneously in the published human study.
- 2
Reported to bind circulating albumin via the DAC moiety, prolonging systemic exposure.
- 3
Proposed to act at the GHRH receptor on pituitary somatotrophs.
- 4
Researchers reported that single and multiple doses produced sustained, dose-dependent elevations in GH and IGF-1 over several days in healthy adults.
What the research has looked at
Single human pharmacology trial
- Teichman et al. (J Clin Endocrinol Metab, 2006) reported prolonged, dose-dependent increases in GH and IGF-1 lasting roughly 6 to 11 days after a single dose, with sustained IGF-1 elevation across multiple doses, in healthy adult volunteers.
- No independent replication or larger trial was located, so this remains single-study evidence.
Strength of evidence: Limited human evidence
One verifiable human pharmacology study exists, without replication, long-term safety data, or any efficacy-in-disease endpoint.
Some human data exist, but they are small, short, or not designed to answer the questions people ask online.
Reported cautions and unknowns
- The single identified human trial reported injection-site reactions and generally mild adverse events.
- That study reported IGF-1 staying elevated for days to weeks after dosing, which the authors flagged as the intended but monitorable effect.
- No long-term human safety, cardiovascular or oncological data specific to CJC-1295 were located.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
CJC-1295 with DAC questions people ask
How do you reconstitute CJC-1295 with DAC?
A common starting point for a 5 mg vial of CJC-1295 with DAC is 2 mL of bacteriostatic water, which gives 2.5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of CJC-1295 with DAC is one dose?
At 2.5 mg per mL, that works out to about 80 units on a U-100 insulin syringe for a 2000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for CJC-1295 with DAC?
Published and community sources describe 1–2 mg, subcutaneous, once weekly, typically run 8 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should CJC-1295 with DAC be stored?
Lyophilized CJC-1295 with DAC vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.